Australia's largest stock trading and investment forum Australia's #1 stock forum

BAL

Click for more information

0.00%

$13.23 bellamy's australia limited

BAL_Should go private!, page-5

First 5 Last

Share
Profile

Follow
usc75

7,026 Posts.

181

08/09/18

13:29

Post #: 35476815
Share

Originally posted by sandy68 ↑

With the company making a lot in revenues, very profitable, earnings growing, dollar depreciating, and the market not recognising the value proposition, I’m wondering if BAL may ever think of going private. Going private at this time could be highly strategic, what do you all think? Valuations is too cheap on simple discounted future earnings.

Realist again after laying foundation to annihilate overseas brand baby food. It has the platform already to do it, just more effective market penetration. Private equity market in Hongkong could have enough money in cash lying around being eroded away by inflation and the dollar is cheap. Even the US has the same problem I heard. Too much cash eroding away.

Go private, raise capital privately and come out super strong on the other side. Perhaps this idea could be explored at the AGM if enough people ask for it.

Share your thought please.

Expand

If your "theory" or "wishes" are right, then maybe it's the reason Share Price is tanking!

And if so, then keep tanking???

BAL Price at posting: $9.77 Sentiment: Sell Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 4 more messages in this thread...

First 5 Last

Add BAL (ASX) to my watchlist